Aequus Pharmaceuticals, Inc.’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Aequus develops and commercializes therapeutic products for the treatment of ophthalmology and neurological disorders. Read more

5 Followers on Owler
5 Followers on Owler
5 Followers on Owler
5 Followers on Owler

Aequus develops and commercializes therapeutic products for the treatment of ophthalmology and neurological disorders. Read more

Doug Janzen's photo - Chairman & CEO of Aequus Pharmaceuticals, Inc.

Chairman & CEO

Doug Janzen

CEO Approval Rating

81/100

Founded:

2013

Status:

PublicIndependent CompanyTMX Group - Toronto Stock ExchangeAQS

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cerecin is perceived as one of Aequus Pharmaceuticals, Inc.'s biggest rivals. Cerecin's headquarters is in Singapore, Central Singapore, and was founded in 2001. Cerecin operates in the Pharmaceuticals industry. Cerecin generates 744% of Aequus Pharmaceuticals, Inc.'s revenue.

Cortexyme has been one of Aequus Pharmaceuticals, Inc.'s top competitors. Cortexyme is a Public company that was founded in 2012 in South San Francisco, California. Cortexyme is in the Biotechnology field. Compared to Aequus Pharmaceuticals, Inc., Cortexyme has 18 more employees.

Alzheon is Aequus Pharmaceuticals, Inc.'s #3 rival. Alzheon was founded in Framingham, Massachusetts} in 2013. Alzheon operates in the Biotechnology industry. Compared to Aequus Pharmaceuticals, Inc., Alzheon generates $7.1M more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Cernium a competitor of Aequus Pharmaceuticals, Inc.?

Quarterly and Annual Revenue

Coming soon for Aequus Pharmaceuticals, Inc.!

Annual Revenue

$ < 1M

Aequus Pharmaceuticals, Inc.'s revenue is the ranked 18th among it's top 10 competitors. The top 10 competitors average 241M.

Acquisitions

No recent acquisitions found related to Aequus Pharmaceuticals, Inc.

Aequus Pharmaceuticals, Inc. Funding History

$2.7M$3.5M$5.9M

Since Aequus Pharmaceuticals, Inc. was founded in 2013, it has participated in 4 rounds of funding. In total Aequus Pharmaceuticals, Inc. has raised $5.9M. Aequus Pharmaceuticals, Inc.'s last funding round was on May 2019 for a total of $2.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
May 2019
$2.3M
-
Private Placement
Aug 2018
$775K
-
Equity
Sep 2016
$2.1M
-
Equity
Jan 2016
$628.8K
-

Since Aequus Pharmaceuticals, Inc. was founded in 2013, it has participated in 4 rounds of funding. In total Aequus Pharmaceuticals, Inc. has raised $5.9M. Aequus Pharmaceuticals, Inc.'s last funding round was on May 2019 for a total of $2.3M

Investments

No recent investments found related to Aequus Pharmaceuticals, Inc.

Aequus Pharmaceuticals, Inc. News

October 30, 2020Equity Guru

Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market

Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescri... See more »
October 29, 2020Proactive Investors

Aequus and partner Medicom Healthcare win Medical Device License for Evolve Daily Intensive product to treat dry eye disease

The formulation contains 350 drops that can be dispensed with gentle squeezing - an important feature... See more »
October 19, 2020Equity Guru

Aequus Pharmaceuticals (AQS.V) gets Health Canada device licence approval, validates business model

Aequus Pharmaceuticals (AQS.V), a specialty pharma company with a business model of acquiring and re-... See more »
October 19, 2020Proactive Investors

Aequus and partner Medicom Healthcare win Medical Device License for Evolve Intensive Gel to treat Dry Eye Disease

The formulation will be made available in an easy-squeeze eye drop bottle containing 360 drops and no... See more »
October 16, 2020Proactive Investors

Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada

CEO Doug Janzen sees considerable room for growth over the next 12 months for tacrolimus, as Aequus p... See more »
September 22, 2020MarketScreener

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

(marketscreener.com) VANCOUVER, British Columbia, Sept. 22, 2020 -- Aequus Pharmaceuticals Inc. , a s... See more »
September 14, 2020Proactive Investors

Aequus Pharmaceuticals files new medical device licenses for Evolve dry eye products in Canada

Aequus and UK-based Medicom Healthcare have a license agreement granting Aequus exclusive rights to c... See more »

Aequus Pharmaceuticals, Inc. Press Releases

June 1, 2020centralcharts

Aequus Provides General Update and First Quarter 2020 Financial Highlights

VANCOUVER, British Columbia, June 01, 2020 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQ... See more »
May 4, 2020centralcharts

Aequus Pharmaceuticals off to a great start in 2020 after record 4th quarter in 2019

Aequus Pharmaceuticals (CVE:AQS-OTCQB: AQSZF) Chairman and CEO Doug Janzen joined Steve Darling from ... See more »
March 23, 2020Business Press 24

A Message from the CEO of Aequus Pharmaceuticals<br />

VANCOUVER, March 23rd, 2020 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus or the C... See more »
February 3, 2020GlobalNewswire

Aequus and Medicom Announce Changes to their Respective Commercial Leadership Teams

VANCOUVER, British Columbia, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQ... See more »
January 16, 2020Business Press 24

Aequus Receives Positive Formulary Decision in British Columbia for Specialty Portfolio Product<br />

VANCOUVER, January 16th 2020 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus or the ... See more »
September 17, 2019GlobeNewswire

Aequus Replaces Expired Short Form Base Shelf Prospectus

NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES... See more »
July 29, 2019Business Press 24

Aequus Signs Exclusive Distribution Agreement with Medicom Healthcare for Canadian Distribution Rights of Ophthalmic Products<br />

VANCOUVER, BC July 29, 2019 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (Aequus or the C... See more »

Social Media

Headquarters

2820-200 Granville Street

Vancouver, British ColumbiaV6C 1S4

604-336-7906

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Aequus develops and commercializes therapeutic products for the treatment of ophthalmology and neurological disorders. Aequus Pharmaceuticals, Inc. was founded in 2013. Aequus Pharmaceuticals, Inc.'s headquarters is located in Vancouver, British Colum...

CEO

Aequus Pharmaceuticals, Inc.'s Chairman & CEO, Doug Janzen, currently has an approval rating of 81%. Aequus Pharmaceuticals, Inc.'s primary competitors are Cerecin, Cortexyme & Alzheon.

Website

aequuspharma.ca

Frequently Asked Questions about Aequus Pharmaceuticals, Inc.

  1. When was Aequus Pharmaceuticals, Inc. founded?

    Aequus Pharmaceuticals, Inc. was founded in 2013
  2. Who is Aequus Pharmaceuticals, Inc.'s CEO?

    Aequus Pharmaceuticals, Inc.'s CEO is Doug Janzen
  3. How much revenue does Aequus Pharmaceuticals, Inc. generate?

    Aequus Pharmaceuticals, Inc. generates $ < 1M in revenue
  4. How much funding does Aequus Pharmaceuticals, Inc. have?

    Aequus Pharmaceuticals, Inc. has historically raised $5.9M in funding
  1. Where is Aequus Pharmaceuticals, Inc.'s headquarters?

    Aequus Pharmaceuticals, Inc.'s headquarters is in Vancouver British Columbia, CA
  2. How many employees does Aequus Pharmaceuticals, Inc. have?

    Aequus Pharmaceuticals, Inc. has 5 employees
  3. What sector does Aequus Pharmaceuticals, Inc. operate in?

    Aequus Pharmaceuticals, Inc. is in Health Care Services
  4. Who are Aequus Pharmaceuticals, Inc.'s competitors?

    Aequus Pharmaceuticals, Inc.'s top competitors are Cerecin, Cortexyme, Alzheon